News

¹¹¹In/²²⁵Ac-ABD320, a novel 5T4-targeted radiopharmaceutical with favorable tumor-to-normal tissue biodistribution and single-dose efficacy in preclinical cancer models

Trial in Progress: A Phase 1a/b, Open-Label, Dose-Escalation Study of ²²⁵Ac-ABD147 for Locally Advanced or Metastatic Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-Based Chemotherapy